Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).
Provided byGuidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.
No results were found
11 Sep 2023
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending UCB's Bimzelx (bimekizumab), with the inflammatory disease drug now authorised by the institute to treat ... NICE’s guidance follows a recent
11 Sep 2023
According to NICE’s draft guidance, around 180, 000 people living with difficult-to-manage type 2 diabetes could benefit from the new treatment option. ... The recommendation follows additional analyses and modelling on clinical and cost-effectiveness
8 Sep 2023
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Camzyos (mavacamten) for use across NHS England and Wales in adults with symptomatic ... Following NICE’s final guidance, Camzyos
4 Sep 2023
The NICE committee concluded that the treatment would be an additional ERT for patients with and without an amenable mutation and was a relevant comparator to existing treatments. ... The treatment is the first ERT recommended for routine NHS use by NICE.
21 Aug 2023
NICE’s decision marks the first time the institute has recommended an EB treatment, with around 670 patients in England expected to benefit from Filsuvez. ... Helen Knight, director of health technology assessment at NICE, said: "There are substantial
MGP’sGuidelinesbrand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. ThroughGuidelines,指导护士andGuidelines in Practice,MGPconnect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.
To discuss how we can support your guidance or implementation needs please contactmarketing@mgp.co.uk
No results were found
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
